Prahlad Singh, PerkinElmer
PerkinElmer hits the checkbook again, this time doling out $260M for next-gen therapy bioservices firm
When PerkinElmer iced a deal to pick up UK gene editing firm Horizon Discovery, it trumpeted its big move into next-gen therapeutics. Now, not …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
